Dulaglutide: Nursing Drug Guide, Hypoglycemia & NCLEX Review
Dulaglutide (Trulicity) is a once-weekly GLP-1 injection for type 2 diabetes—often combined with metformin, sulfonylureas, or insulin. The bedside priority is preventing hypoglycemia when secretagogues or insulin are co-prescribed, recognizing pancreatitis and dehydration from GI effects, and counseling on the thyroid C-cell tumor boxed warning before the first pen dose.
Thyroid C-cell tumors: Dulaglutide caused thyroid C-cell tumors in rats; whether Trulicity causes medullary thyroid carcinoma (MTC) in humans is unknown. Contraindicated with personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2). Teach neck mass, dysphagia, dyspnea, or persistent hoarseness.
Hypoglycemia: Concomitant insulin secretagogues (e.g., sulfonylureas) or insulin increase hypoglycemia risk, including severe hypoglycemia, per Trulicity labeling—reduce those doses when starting dulaglutide and monitor capillary glucose. Pancreatitis: Discontinue promptly if pancreatitis is suspected; do not restart if confirmed.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every Trulicity dose, confirm the patient is not vomiting or unable to keep fluids down, check capillary glucose if on insulin or a sulfonylurea, verify the pen strength matches the order (0.75–4.5 mg), and hold for persistent severe abdominal pain suggestive of pancreatitis. Teach hypoglycemia treatment and when to call for thyroid symptoms or dehydration.
Most common brand names
Dulaglutide is the generic name for a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous pen. The primary U.S. brand is Trulicity.
Trulicity pens are single-dose devices in strengths of 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg per 0.5 mL. Do not confuse with other weekly GLP-1 pens (e.g., semaglutide or liraglutide) or with rapid-acting insulin pens stored in the same refrigerator.
Why we give it — Indications
Trulicity (dulaglutide) is used as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus. It is also indicated to reduce major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is not for type 1 diabetes.
| Use | Detail |
|---|---|
| Type 2 diabetes — glycemic control | Once-weekly subcutaneous injection added to diet and exercise; may be combined with metformin, sulfonylureas, or insulin per prescriber plan |
| Cardiovascular risk reduction (adults) | Reduces risk of cardiovascular death, non-fatal MI, or non-fatal stroke in adults with type 2 diabetes and established CV disease or multiple CV risk factors (REWIND trial per labeling) |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Dulaglutide activates the GLP-1 receptor on pancreatic beta cells, increasing glucose-dependent insulin release, decreasing glucagon secretion, and slowing gastric emptying. Nurses see the clinical result as lower fasting and postprandial glucose and often weight loss—but also more nausea and delayed gastric emptying. When insulin or sulfonylureas are continued, hypoglycemia risk rises even though dulaglutide alone rarely causes severe hypoglycemia without those agents.
Dosing overview
Verify the pen strength and weekly day against current Trulicity prescribing information. Titrate only per prescriber—labeling requires at least 4 weeks on the current dose before increasing.
Missed dose: If ≥3 days (72 hours) remain before the next scheduled dose, give the missed dose as soon as possible. If <3 days remain, skip the missed dose and give the next dose on the regular day, then resume the weekly schedule (Trulicity labeling).
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset | Fasting and postprandial glucose lowering observed after a single dose in labeling pharmacodynamics | Teach that GI side effects may appear before full glycemic benefit |
| Peak (SC) | Tmax at steady state 24–72 hours (median 48 hours) | Weekly scheduling—not daily; largest gastric-emptying delay often after first dose |
| Half-life | ~5 days | Missed-dose rules use 72-hour window before next scheduled injection |
| Duration / steady state | Steady state in ~2–4 weeks with once-weekly dosing | Trend HbA1c over months; monitor glucose when combined with insulin or secretagogues |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm type 2 diabetes indication—not for type 1 diabetes per labeling
- Screen personal/family history of medullary thyroid carcinoma (MTC) and MEN 2; review neck symptoms and prior GLP-1 hypersensitivity
- Reconcile insulin, sulfonylurea (e.g., glipizide), or insulin glargine doses; complete medication reconciliation and hypoglycemia teaching before first injection
Contraindications
- Personal or family history of MTC or MEN 2 (boxed warning)
- Serious hypersensitivity to dulaglutide or product components (anaphylaxis or angioedema reported)
- Not recommended in severe gastrointestinal disease, including severe gastroparesis (not studied)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Insulin secretagogues / insulin | Increased hypoglycemia risk, including severe hypoglycemia (labeled warning) | Confirm reduced SU/insulin dose when dulaglutide starts; teach hypoglycemia symptoms; check capillary glucose per protocol |
| Oral medications (delayed gastric emptying) | Dulaglutide slows gastric emptying; may impact absorption of oral drugs | Flag narrow-index oral drugs to pharmacy; monitor clinical effect when starting or escalating dulaglutide |
| Other GLP-1 receptor agonists | Duplicate incretin therapy increases adverse effects without benefit | Hold duplicate orders; verify only one GLP-1 agonist on MAR |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Subcutaneous injection once weekly via Trulicity single-dose pen into abdomen, thigh, or upper arm; rotate sites with each dose per labeling.
- Train patient/caregiver on pen technique before first home dose; inspect solution—clear and colorless; do not use if cloudy, discolored, or particulate
- When using with insulin, administer as separate injections—never mix in the same syringe; same body region is acceptable but injections should not be adjacent
- Refrigerate pens; do not freeze; protect from light; follow Instructions for Use for room-temperature storage limits
Match the ordered milligram strength (0.75, 1.5, 3, or 4.5 mg) to the pen label every time. If the patient takes insulin or a sulfonylurea, assess for hypoglycemia before injection and ensure fast-acting carbohydrate is available.
Expected therapeutic response
- Lower fasting and postprandial glucose; downward trend in HbA1c over weeks to months
- Modest weight loss may occur—document baseline weight and ongoing trend
- Cardiovascular risk reduction in indicated adults is a long-term outcome—continue nursing surveillance for hypoglycemia and GI tolerance
Red flags — Stop and act
GLP-1 therapy can mask worsening glycemia when vomiting prevents intake, or unmask hypoglycemia when insulin doses are not reduced. Escalate early for abdominal pain and dehydration.
- Persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting—suspect pancreatitis; discontinue per labeling
- Glucose <54 mg/dL or severe hypoglycemia requiring assistance—treat immediately; review insulin/secretagogue doses
- Anaphylaxis, angioedema, or serious systemic hypersensitivity after injection
- Prolonged GI losses with oliguria or dizziness—suspect dehydration-related acute kidney injury; monitor intake and renal function
- New neck mass, dysphagia, dyspnea, or persistent hoarseness—thyroid tumor symptoms per boxed warning counseling
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Nausea, diarrhea, vomiting, abdominal pain | Very common; GI events led to discontinuation more often than placebo in trials | Small frequent meals, hydration teaching; hold and escalate if severe or persistent; monitor renal function with volume loss |
| Hypoglycemia (with insulin or secretagogue) | Increased risk when combined; severe hypoglycemia reported | Verify dose reductions of SU/insulin at initiation; teach recognition and 15–15 rule per protocol |
| Injection-site reactions | Reported; higher in pediatric patients than adults per labeling | Rotate sites; distinguish local reaction from cellulitis |
| Acute pancreatitis | Labeled warning; discontinue if suspected; do not restart if confirmed | Stop drug, notify prescriber, supportive care and serial assessment per protocol |
| Hypersensitivity (anaphylaxis, angioedema) | Postmarketing serious reactions | Discontinue permanently; emergency treatment per anaphylaxis protocol |
| Acute gallbladder disease, diabetic retinopathy complications, acute kidney injury | Labeled warnings | Right upper quadrant pain → gallbladder evaluation; retinopathy history → monitor vision; GI losses → renal monitoring |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdoses have been reported in Trulicity clinical studies. Associated effects were primarily mild or moderate gastrointestinal events (e.g., nausea, vomiting) and non-severe hypoglycemia per labeling.
Overdose management
- Antidote: Not specified in the reviewed prescribing information—no specific reversal agent listed
- Initiate supportive care based on clinical signs and symptoms; monitor plasma glucose frequently
- Contact local poison control / toxicology services per facility protocol and local emergency guidance for additional direction
Look-alike / sound-alike and error prevention
- Trulicity vs other GLP-1 pens—weekly dulaglutide vs semaglutide or daily liraglutide; verify drug name and day of week on MAR
- Trulicity vs Humalog (insulin)—separate refrigerator storage and labeling; similar “Tru-” prefixes increase pick risk
- Strength confusion—0.75 mg vs 1.5 mg vs 3 mg vs 4.5 mg pens; all are 0.5 mL volume—read milligrams, not volume alone
- Duplicate incretin therapy—do not administer two GLP-1 agonists concurrently
- Weekly schedule errors—document chosen injection day; teach 72-hour missed-dose rule to prevent double weekly doses
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Not applicable—subcutaneous prefilled pen/syringe only |
| Food timing | Not applicable to route; no fasting requirement specified for SC injection |
| Storage | Refrigerate per product labeling; allow 15–30 minutes at room temperature before injection; protect from light/freezing per Instructions for Use |
| Site rotation | Alternate thigh and abdomen; avoid tender, bruised, red, or hard areas |
| Missed dose | If ≥72 hours before next dose, give now; if <72 hours, skip and take next scheduled dose—do not double |
| Commonly missed | Not reducing insulin/SU when GLP-1 starts; giving two weekly injections after a missed dose |
| Ask pharmacy when | Pen device change, renal impairment with severe GI symptoms, or overlapping GLP-1 orders |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults (≥65) on insulin or sulfonylureas | Higher hypoglycemia vulnerability—use lower glucose targets cautiously and teach family assistance with severe hypoglycemia |
| Renal impairment / ESRD | No dose adjustment, but monitor renal function with severe GI reactions; acute kidney injury reported with dehydration per labeling |
| History of diabetic retinopathy | Retinopathy complications reported more often in patients with prior retinopathy in CV outcomes trial—coordinate ophthalmology follow-up |
| Pregnancy | Limited human data; animal studies showed fetal risk at high exposures. Use during pregnancy only if potential benefit justifies potential fetal risk; poorly controlled diabetes also harms pregnancy—MDT decision. |
| Lactation | No human milk data for dulaglutide per labeling. Balance breastfeeding benefits with maternal treatment needs and potential infant effects from maternal condition or drug. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Capillary blood glucose and blood glucose monitoring when combined with insulin or secretagogues—especially after dose changes
- HbA1c trend, weight, blood pressure, renal function (creatinine/eGFR) with persistent GI losses
- Abdominal pain pattern, hydration status, injection sites, and thyroid symptom screening per boxed warning counseling
Document
- Pen strength (mg), injection site, day of week, patient/caregiver education completion, and tolerance
- Hypoglycemia episodes, hold actions, prescriber/pharmacy notification for pancreatitis or hypersensitivity suspicion
- Co-administered diabetes medications and any insulin/SU dose reductions at initiation
Patient teaching
- Know hypoglycemia symptoms (shakiness, sweating, confusion)—keep fast-acting carbohydrate available if using insulin or a sulfonylurea
- Report persistent severe stomach pain, especially if radiating to the back, or ongoing vomiting—do not take the next dose until the prescriber advises
- Stay hydrated if nausea or diarrhea occur; seek care for signs of dehydration
- Rotate weekly injection sites; report neck lump, hoarseness, trouble swallowing, or breathing problems
- Follow the 72-hour missed-dose rule—never take two weekly doses within 3 days without prescriber instruction
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Suspected acute pancreatitis (persistent severe abdominal pain, with or without vomiting)—hold and notify prescriber; discontinue if confirmed
- Symptomatic hypoglycemia until treated and insulin/secretagogue doses reviewed
- Serious hypersensitivity or anaphylaxis after any dose—do not rechallenge
- Personal/family history of MTC or MEN 2 not previously cleared—do not administer
- Wrong pen strength, cloudy/particulate product, expired pen, or planned duplicate GLP-1 dose within the same week
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Diabetes clinic and med-surg nurses often teach weekly Trulicity self-injection while insulin or sulfonylureas remain on the MAR. Build hypoglycemia prevention and pancreatitis recognition into every visit—not only the first pen training.
1. Check-before-you-give protocol
- Right patient, drug (dulaglutide), pen strength (mg), route, and weekly day
- Capillary glucose if on insulin or secretagogue; assess for nausea, vomiting, or abdominal pain
- Screen MTC/MEN 2 history and thyroid symptoms; confirm no duplicate GLP-1 on MAR
- Inspect pen solution, refrigeration status, site rotation, and patient/caregiver pen competency
2. High-alert and safety badge
Not a traditional high-alert medication, but carries a boxed warning and severe hypoglycemia risk with insulin/secretagoguesUse insulin-style safety rigor for glucose checks, dose-reduction verification, and pancreatitis holds even when patients self-administer at home.
3. Clinical workflow: hold and question rules
- If glucose is symptomatically low, treat hypoglycemia first, hold dulaglutide if vomiting prevents intake, and notify prescriber to review insulin/SU doses
- Persistent severe abdominal pain → hold dulaglutide, notify prescriber same day; discontinue if pancreatitis confirmed
- Wrong pen strength or duplicate weekly dose within 72 hours → hold and call pharmacy before injecting
4. Critical teach-back questions
- “What should you do if you miss your weekly injection?” (Patient should describe the 72-hour rule: take if ≥3 days remain before next dose; otherwise skip and take the next scheduled dose—never double without prescriber advice.)
- “What symptoms mean you should stop the pen and call your care team?” (Patient should name severe stomach pain, ongoing vomiting, signs of low blood sugar, or neck lump/hoarseness.)
5. Care coordination
Prescriber / endocrinology: Titrate dulaglutide, adjust insulin/secretagogue doses at initiation, manage pancreatitis or retinopathy concerns
Pharmacist: Pen device training, LASA checks with other GLP-1 or insulin products, renal monitoring with severe GI adverse reactions
🧠 Quick mental checklist
- Is the patient on insulin or a sulfonylurea—and was the dose reduced when dulaglutide started?
- Any severe abdominal pain, vomiting, or dehydration since the last dose?
- Does the pen strength (mg) match the order—not just 0.5 mL volume?
- When is the next weekly dose due—and was a missed dose handled with the 72-hour rule?
- MTC/MEN 2 history cleared and thyroid symptoms reviewed?
Dulaglutide NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for dulaglutide using a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), glucose trend interpretation, matrix urgency sorting, clinical judgment, and missed-dose cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Trulicity (dulaglutide) 1.5 mg subcutaneous once weekly — due today 0900; held pending assessment
- Metformin 1000 mg PO BID — given with breakfast
- Glipizide 5 mg PO daily before breakfast — given 0730
- Insulin glargine 22 units subcutaneous at bedtime — last dose 2100 yesterday
- Pharmacy note: glipizide dose not reduced when dulaglutide started 2 weeks ago
- Admission HbA1c 8.4%; BMP today: glucose 54 mg/dL (critical), creatinine 1.0 mg/dL, eGFR 72 mL/min
- Prior trend: fasting glucose 140–165 mg/dL before dulaglutide; no prior <70 mg/dL documented this admission
- Lipase/amylase ordered for abdominal pain — results pending
- 0900: HR 108; BP 148/92; RR 18; SpO2 98% on room air; temp 36.8 °C
- Patient reports diaphoresis and shakiness; alert and oriented ×4
- Intake: sips of water only since 0600 because of nausea; urine output decreased per I&O
- 0730: Nausea × 2 days since dulaglutide dose increase; no vomiting yet
- 0845: Fingerstick 54 mg/dL after breakfast; patient ate 15 g glucose tabs; recheck ordered
- 0900: Nurse held scheduled Trulicity; notified prescriber and pharmacy about unchanged glipizide
- Patient asks whether to take tonight’s insulin glargine if glucose stays low
Answer key & rationale
Frequently asked questions
When should a nurse hold dulaglutide and contact the prescriber?
Hold for suspected acute pancreatitis, confirmed pancreatitis, serious hypersensitivity, symptomatic hypoglycemia until treated, MTC/MEN 2 contraindications, wrong pen strength, or duplicate weekly dosing. Trulicity labeling directs discontinuation if pancreatitis is suspected and not restarting if confirmed.
Why does dulaglutide increase hypoglycemia risk?
Concomitant insulin secretagogues or insulin increase hypoglycemia risk, including severe hypoglycemia, per Trulicity labeling. Reduce sulfonylurea or insulin doses when initiating dulaglutide and teach patients to recognize and treat low blood glucose.
What adverse effects are most common on dulaglutide?
Placebo-controlled trials report nausea, diarrhea, vomiting, abdominal pain, decreased appetite, dyspepsia, and fatigue more often than placebo. Serious labeled concerns include pancreatitis, hypersensitivity, acute kidney injury from GI fluid loss, gallbladder disease, and diabetic retinopathy complications in patients with prior retinopathy.
What is the boxed warning for dulaglutide?
Dulaglutide caused thyroid C-cell tumors in rats; human relevance is unknown. Trulicity is contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2. Counsel patients on neck mass, dysphagia, dyspnea, or persistent hoarseness.
Is there an antidote for dulaglutide overdose?
Not specified in the reviewed prescribing information. Overdoses in studies caused mainly mild or moderate GI events and non-severe hypoglycemia. Provide supportive care with frequent plasma glucose monitoring; contact poison control or medical toxicology per facility protocol.
How should nurses manage a missed weekly dulaglutide dose?
If at least 3 days (72 hours) remain before the next scheduled dose, give the missed dose as soon as possible. If less than 3 days remain, skip the missed dose and give the next dose on the regular day, then resume the weekly schedule per Trulicity labeling.
References
-
U.S. National Library of Medicine. TRULICITY (dulaglutide) injection — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58353438-3236-4596-9324-62fed9615cb7
-
U.S. Food and Drug Administration. Trulicity (dulaglutide) prescribing information label PDF.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s036lbl.pdf
-
Eli Lilly and Company. Trulicity (dulaglutide) U.S. prescribing information.https://pi.lilly.com/us/trulicity-uspi.pdf
-
American Diabetes Association. Standards of Care in Diabetes.https://diabetesjournals.org/care/issue/49/Supplement_1
-
Institute for Safe Medication Practices. ISMP List of High-Alert Medications in Acute Care Settings (insulin and hypoglycemic agents).https://www.ismp.org/recommendations/high-alert-medications-acute-list
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.